Get started
Author

Sofia Klopp-Savino

Observed names: S. Klopp-Savino, Sofia Klopp Savino
Observed institution: aTyr Pharma (United States)
ORCID: 0000-0003-0509-8935
Observed ORCID: 0000-0003-0509-8935
OpenAlex ID: A5012481584
Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer
2023 · Zhiwen Xu, Hira Lal Goel, et al. · Science Translational Medicine · 49
PDF
A human histidyl-tRNA synthetase splice variant therapeutic targets NRP2 to resolve lung inflammation and fibrosis
2025 · Leslie A. Nangle, Zhiwen Xu, et al. · Science Translational Medicine · 16
Efzofitimod: a novel therapeutic candidate for SSc-ILD
2023 · David Siefker, Zhiwen Xu, et al. · European Respiratory Journal · 2
699 ATYR2810 an anti-NRP2 monoclonal antibody targets tumor-associated macrophages
2021 · Samantha Tyler, Michaela Ferrer, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Natural Asp-tRNA synthetase fragment targets myofibroblasts to abrogate tissue fibrosis
2026 · Ryan A. Adams, Ying-Ting Wang, et al. · Journal of Biological Chemistry
Efzofitimod Is an Immunomodulator of Myeloid Cell Function and Novel Therapeutic Candidate for Interstitial Lung Diseases
2024 · D. Siefker, Z. Xu, et al. · American Journal of Respiratory and Critical Care Medicine
Efzofitimod, a Novel Immunomodulator for Pulmonary Sarcoidosis, Modulates Patient Inflammatory Responses Through Myeloid Cells
2023 · D. Siefker, S. Paz, et al. · American Journal of Respiratory and Critical Care Medicine
Abstract 1758: Resistance to cancer therapy via upregulation of the NRP2/VEGF-C axis can be neutralized by ATYR2810
2023 · Alison Barber, Zhiwen Xu, et al. · Cancer Research
Abstract LB085: ATYR2810, a fully humanized monoclonal antibody targeting the VEGF-NRP2 pathway sensitizes highly aggressive and chemoresistant TNBC subtypes to chemotherapy
2022 · Zhiwen Xu, Alison Barber, et al. · Cancer Research
Works count: 9
Citation count: 68
H-index: 2
I10-index: 2
Year
Topic
Type